(4-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-3-nitrophenyl)boronic acid

Catalog No. :
ACZJMB253
CAS No. :
2828444-20-6
Molecular Formula :
C15H22BN3O6
Molecular Weight :
351.17

IUPAC Name:(4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-3-nitrophenyl)boronic acid

(4-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-3-nitrophenyl)boronic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(4-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-3-nitrophenyl)boronic acid
IUPAC Name(4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-3-nitrophenyl)boronic acid
Molecular FormulaC15H22BN3O6
Molecular Weight351.17
SMILESO=[N+](C1=CC(B(O)O)=CC=C1N2CCN(C(OC(C)(C)C)=O)CC2)[O-]
InChI KeyCWWMJUKEROWEQQ-UHFFFAOYSA-N
Synonym(4-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-3-nitrophenyl)boronic acid;1-Piperazinecarboxylic acid, 4-(4-borono-2-nitrophenyl)-, 1-(1,1-dimethylethyl) ester
CAS No.2828444-20-6
PubChem CID164186597

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H315-H319
Precautionary Statement(s)
P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364

Synthetic Route by SureRoute

1. ACZJMB253 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. ACUGLN971 route compound structure diagram
    ACUGLN971352530-22-4 In Stock
  4. Then
  5. ACZJMB253 route product structure diagram
    ACZJMB2532828444-20-6
Inquiry

2. ACZJMB253 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. ACZRQD591 route compound structure diagram
    ACZRQD591151169-67-4 In Stock
  4. Then
  5. ACZJMB253 route product structure diagram
    ACZJMB2532828444-20-6
Inquiry

Comments (0)